A Medical Device Daily

Cardiovascular Systems (St. Paul, Minnesota) has signed an exclusive distribution agreement with Asahi Intecc (Nagoya, Japan) to market its peripheral guide wire line in the U.S.

"The addition of Asahi guide wires expands our product portfolio and reinforces our leadership position in the peripheral arterial disease or PAD market," said David Martin, CSI president/CEO. "Asahi peripheral guide wires address long, complex lesions above or below the knee, and complement the plaque removal capabilities of our Diamondback 360 . This agreement supports our mission to provide the more than 5,000 physicians and 2,000 hospitals treating PAD with comprehensive endovascular tools. In just a few minutes of treatment time the Diamondback 360 can keep patients walking and helps patients and their families avoid the high economic costs and trauma related to immobility and amputation."

CSI's flagship product is the Diamondback 360 Peripheral Arterial Disease System, a minimally invasive catheter system for treating PAD. Between eight million and 12 million Americans suffer from PAD, which is caused by the accumulation of plaque in leg or foot arteries, reducing blood flow. Symptoms include leg pain when walking or at rest, and PAD can lead to tissue loss and eventually limb amputation. The Diamondback 360o removes calcified and fibrous plaque and restores blood flow in vessels both below and above the knee.

CSI will offer two Asahi 0.18 wire platforms: the Astato 30 and Treasure 12. The Astato 30 is a high-penetration guide wire specially designed to break through fibrous caps and calcium deposits, and treat long, complex lesions. The Treasure 12 has a one-piece core which provides exceptional control, superior torque performance and tactile feedback to the physician.